News Release

Interim Analysis Completed For Tectin™ Phase IIA Severe Cancer Related Pain Trial

Date: October 21, 2003

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company" is pleased to announce the completion of an interim analysis of its Phase IIa trial on patients with advanced cancer disease who had not achieved adequate pain relief employing current established drug therapies.

The two primary objectives of the study are to evaluate safety at a variety of dose levels of Tectin™ and characterize its analgesic activity. Based on the results of the interim analysis and in line with the recommendation of its clinical advisors and investigators, the Company will file a Clinical Trial Application (CTA) with Health Canada to begin a Phase IIb/III pivotal trial.  The CTA application for the pivotal trial is anticipated to be filed within the next 30 days.

The Company plans to publish the results of the Phase IIa trial in a peer-reviewed journal.

International Wex Technologies Inc., a publicly listed neuro-bioscience Company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, a sodium channel blocker, is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

For additional information on our products, view the Company website at http://www.wextech.ca or call Gordon Stanley at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.